The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | New therapies strengthening treatment choice in second-line DLBCL
Gareth Gregory, MBBS, PhD, FRACP, FRCPA, Fiona Stanley Hospital & Monash University, Perth, Australia, discusses emerging second-line treatments for diffuse large B-cell lymphoma (DLBCL), including bispecific antibodies, autologous and allogeneic CAR T-cell therapies, and small molecule inhibitors. Based on early data from the Phase III STARGLO trial (NCT04408638), Dr Gregory anticipates that bispecifics will be practice-changing in the second-line and later settings. However, he notes that selecting the optimal therapy for each patient remains a key challenge. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The treatment landscape in second-line, DLBCL, is becoming very crowded which is very exciting. Indeed, over the next two years we’re going to see a large number of both bispecific antibodies, novel cellular therapies of autologous and allogeneic CAR-T, and also small molecule inhibitors reading out in registrational Phase II studies. What will be very interesting now is how we prioritise which therapies we give to which patients and hopefully the informed translational research being performed alongside these trials will help to give us some idea of which patients will derive the best benefit from each...
The treatment landscape in second-line, DLBCL, is becoming very crowded which is very exciting. Indeed, over the next two years we’re going to see a large number of both bispecific antibodies, novel cellular therapies of autologous and allogeneic CAR-T, and also small molecule inhibitors reading out in registrational Phase II studies. What will be very interesting now is how we prioritise which therapies we give to which patients and hopefully the informed translational research being performed alongside these trials will help to give us some idea of which patients will derive the best benefit from each. Certainly at this stage the bispecific antibodies having now become available in the third-line showing clinically significant response rates and the early taste of data we’re seeing from studies like STARGLO is indicating that they’ll be probably the more practice-changing in the first instance, but how we sequence these appropriately especially with cellular therapies remains to be defined.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
